MedTrace Logo

Genistein in Treating Patients With Prostate Cancer

NCT01126879 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2019-09-10

Study results available
· View outcomes & findings →

Summary

RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This randomized phase II trial is studying how well genistein works in treating patients with prostate cancer.

Conditions

  • Adenocarcinoma of the Prostate
  • Recurrent Prostate Cancer
  • Stage I Prostate Cancer
  • Stage II Prostate Cancer
  • Stage III Prostate Cancer

Interventions

DIETARY_SUPPLEMENT

genistein

Given orally

OTHER

placebo

Given orally

PROCEDURE

therapeutic conventional surgery

Radical prostatectomy for treatment of prostate cancer

Sponsors & Collaborators

Principal Investigators

  • William Catalona · Northwestern University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-03
Primary Completion
2013-05-09
Completion
2013-12-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01126879 on ClinicalTrials.gov